Medtronic Bets On Future Mazor Robotics Spine Surgery Systems
This article was originally published in Clinica
Executive Summary
Medtronic is putting its sales and marketing power behind Israel-based Mazor Robotics with new commercial agreement and investment deals, both announced May 18.
You may also be interested in...
Device/Diagnostics Quarterly Deal Statistics, Q2 2016
Medtech companies brought in $1.5 billion in Q2 2016, 15% less than Q1, with debt offerings accounting for more than half the total; acquisitions more than doubled due to Abbott's $25 billion takeover of St. Jude Medical. Diagnostics financings were down 34% from Q1 and acquisition volume, also lower, was mainly Thermo Fisher Scientific's $4.2 billion buy of FEI.
Mazor’s Run Of Good News Continues With Trials Presented At IMAST
Data from 848 cases supports the clinical benefits of Renaissance robot-guided spine-surgery over comparable “freehand” minimally invasive procedures, according to the Israeli company.
Medtronic Claims Share Gains In Cardiovascular And Neurostim
The company’s revenue was down just 1% year-over-year in the third quarter of fiscal 2021, despite the ongoing impact of the pandemic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: